- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07442344
Care Bundle for Prevention of Skin Complications and Edema in Restrained Patients (SCER-ICU)
February 27, 2026 updated by: Pinar Erman, Kocaeli City Hospital
Development and Evaluation of the Effectiveness of a Dermatological Complications and Edema Prevention Care Package in the Physical Constraint Zone
Physical restraint (restraint) is defined as the restriction of a patient's free body movements and the prevention of the patient's ability to move easily by healthcare professionals using physical or mechanical devices to prevent the patient from harming themselves or others.
Physical restraints can be used by healthcare professionals for many purposes, particularly in intensive care units, such as ensuring patient safety, controlling aggressive and disruptive behavior, continuing patient care and treatment, and preventing the removal of medical equipment attached to the patient.
However, when looking at the duration of physical restraint applications, it has been determined that they vary between 3-4 days.
The longer the duration of physical restraint, the greater the likelihood of complications developing.
In particular, long-term physical restraint can result in neurovascular and dermatological complications such as pressure injuries, edema, ecchymosis, redness, numbness, limited movement, increased temperature, discoloration, and nerve damage.
The care package application is a model that improves patient care quality by simultaneously and comprehensively implementing 3-5 applications based on strong scientific evidence, prepared for the relevant area in the specified patient group.
Care package applications are created to enable evidence-based practices outlined in guidelines to be used more effectively and practically in clinical settings.
Within this context, the aim of this study is to develop a care package to prevent dermatological complications and edema that may occur in the restraint area in patients undergoing physical restraint in intensive care and to evaluate the effectiveness of this care package.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
76
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: pınar erman, PhD candidate
- Phone Number: +905469417295
- Email: pinarugurag@gmail.com
Study Contact Backup
- Name: Ayşe Ozkaraman, Professor
- Phone Number: 8 +90 239 375 0154
- Email: aozaydin26@hotmail.com
Study Locations
-
-
Izmit
-
Kocaeli, Izmit, Turkey (Türkiye)
- Kocaeli City Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
• 18 years of age or older,
- For whom a physician has decided to apply physical restraint to the upper extremities and is about to begin doing so,
- With intact skin integrity in the area of physical restraint (no lacerations, wounds, ulcerations),
- Without oedema in the area of physical restraint,
- APACHE-2 score of 17 or higher (In the study by Tian et al. (2022), an APACHE-II score of 17 or higher was found to be associated with a low life expectancy),
- Individuals for whom written consent has been obtained from the patient's relatives regarding participation in the study.
Exclusion Criteria:
In the physical restraint area;
- Those with fractures or dislocations,
- Those with peripheral vascular disease or chronic venous insufficiency,
- Those with advanced skin disease (psoriasis, etc.),
- Those whose physical restraint was discontinued within the first 24 hours after it began for any reason (discharge, transfer to another clinic, death, lifting of the physical restraint decision by the physician, etc.).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Care Bundle
Participants in this group will receive structured dermatological complications and an Edema Prevention Care Package in the physical restraint area, in addition to routine nursing care in the intensive care unit.The care package group includes: assessment of the area of physical restraint, application of physical restraint to the upper extremities (both wrists), massage, and elevation.
|
|
|
No Intervention: routine care
Participants in this group will receive routine intensive care unit nursing care without implementation of the structured care bundle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
edema, ecchymosis, laceration, ulceration
Time Frame: From the initiation of physical restraint to the 5th day.
|
The rates of edema, ecchymosis, laceration and ulceration developing in the restricted area in the days following physical restriction.
|
From the initiation of physical restraint to the 5th day.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
March 1, 2026
Primary Completion (Estimated)
March 1, 2027
Study Completion (Estimated)
April 1, 2027
Study Registration Dates
First Submitted
February 19, 2026
First Submitted That Met QC Criteria
February 27, 2026
First Posted (Actual)
March 2, 2026
Study Record Updates
Last Update Posted (Actual)
March 2, 2026
Last Update Submitted That Met QC Criteria
February 27, 2026
Last Verified
February 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Hemorrhage
- Skin Manifestations
- Hematologic Diseases
- Blood Coagulation Disorders
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Hemic and Lymphatic Diseases
- Ulcer
- Ecchymosis
- Edema
- Investigative Techniques
- Environment and Public Health
- Environment
- Environment, Controlled
- Immobilization
- Restraint, Physical
- Weightlessness Simulation
- Space Simulation
- Hindlimb Suspension
Other Study ID Numbers
- 2025-203
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Patient data will only be used for statistical analysis.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
Eye-yon MedicalCompletedCORNEAL EDEMAIsrael, Poland
-
Federico II UniversityCompletedPseudophakic Cystoid Macular Edema
-
Hoffmann-La RocheCompletedDiabetic Macular Edema | Uveitic Macular EdemaUnited States
-
Alexandria UniversityRecruitingDiabetic Macular Edema | Center-involved Diabetic Macular EdemaEgypt
-
Curacle Co., Ltd.Not yet recruitingDiabetic Macular Edema | Diabetic Macular Edema (DME) | DME
-
OcugenRecruitingDiabetic Macular Edema | Center Involved Diabetic Macular EdemaUnited States
-
Postgraduate Institute of Medical Education and...CompletedDiabetic Macular Edema | Vision Disorders | Macular Edema, Cystoid | Clinically Significant Macular EdemaIndia
-
Eye-yon MedicalCompletedChronic Cornel EdemaNetherlands, Israel, Germany, Spain
-
EyePoint Pharmaceuticals, Inc.RecruitingDiabetic Macular Edema | Diabetic Macular Edema (DME) | DMEIsrael, United States, Poland, Germany, Slovakia
Clinical Trials on Evulation
-
Recep Tayyip Erdogan University Training and Research...CompletedMuscle Strength | Sport Injury | Muscle ContractionTurkey